The Discounted Cash Flow (DCF) valuation of Arbutus Biopharma Corp (ABUS) is (19.76) USD. With the latest stock price at 3.13 USD, the upside of Arbutus Biopharma Corp based on DCF is -731.4%.
Based on the latest price of 3.13 USD and our DCF valuation, Arbutus Biopharma Corp (ABUS) is a sell. selling Arbutus stocks now will result in a potential gain of 731.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.3% - 6.5% | 5.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (107.71) - (11.16) | (19.76) |
| Upside | -3541.3% - -456.5% | -731.4% |